Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions
Research article published in American journal of perinatology (2018)
Abstract
INTRODUCTION: The rate of heparin-induced thrombocytopenia (HIT) on a population basis is unknown. The objective of this study was to characterize the risk for HIT during antepartum, delivery, and postpartum hospitalizations in the United States. MATERIALS AND METHODS: A large administrative database was used to determine the risk of HIT in hospitalized obstetric patients who received unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Patients were presumed to have HIT if they were exposed to UFH or LMWH, received a diagnosis of HIT, and were administered a medication for the treatment of HIT including bivalirudin, argatroban, fondaparinux, or lepirudin. We queried severe complications of HIT including arterial thrombosis, limb amputation, heart failure, and death. RESULTS: We identified 66,468 antepartum hospitalizations, 66,741 delivery hospitalizations, and 16,325 postpartum readmissions where women received pharmacologic prophylaxis. Of these, 10 antepartum admissions, 1 delivery admission, and 14 postpartum readmissions involved a diagnosis of HIT with treatment of bivalirudin, argatroban, fondaparinux, or lepirudin. There were no deaths and no diagnoses of arterial thrombosis, limb amputation, heart failure, and death. CONCLUSION: Risk for HIT among hospitalized obstetric patients is low. In this cohort, no cases of death or severe complications were noted in relation to the diagnosis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions.
Por qué esto importa para la hirudoterapia
Este estudio de gran base de datos caracterizó el riesgo de trombocitopenia inducida por heparina (TIH) entre pacientes obstétricas hospitalizadas, identificando 25 casos en total distribuidos entre ingresos de preparto, parto y posparto, dentro de más de 149,000 hospitalizaciones que incluyeron profilaxis con heparina. El estudio identificó los casos de TIH a partir del diagnóstico y la administración de bivalirudina, argatrobán, fondaparinux o lepirudina, y no encontró muertes ni complicaciones graves asociadas. El resumen no aporta información sobre el origen biológico de estos fármacos ni establece ninguna conexión con las sanguijuelas, la hirudina o la hirudoterapia. En consecuencia, este estudio epidemiológico no posee una relevancia defendible dentro del dominio de la ASH relativo a la hirudoterapia o al secretoma de las sanguijuelas.
Citación
Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions
Sagaram D et al. · American journal of perinatology, 2018
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026